Lymphoma - Clinical Research
1 – 20 of 105
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Primary central nervous system lymphomas : EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
(
- Contribution to journal › Article
-
Mark
Primary central nervous system lymphomas : EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
(
- Contribution to journal › Article
-
Mark
Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy
(
- Contribution to journal › Letter
-
Mark
The National Swedish Lymphoma Register – a systematic validation of data quality
(
- Contribution to journal › Article
-
Mark
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
(
- Contribution to journal › Article
-
Mark
Towards improved cervical cancer screening in Ethiopia
2024) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma : the Nordic Lymphoma Group MCL7 VALERIA trial
(
- Contribution to journal › Article
-
Mark
Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome (BIO-MUSE) : Protocol for a Translational Study
(
- Contribution to journal › Article
-
Mark
Tattoos as a risk factor for malignant lymphoma: a population-based case–control study
(
- Contribution to journal › Article
-
Mark
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE) : a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
(
- Contribution to journal › Article
-
Mark
ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
(
- Contribution to journal › Article
- 2023
-
Mark
Evidence for distinct mechanisms of immune suppression in EBV-positive and EBV-negative Hodgkin lymphoma
(
- Contribution to journal › Article
-
Mark
Secondary malignancies among mantle cell lymphoma patients
(
- Contribution to journal › Article
-
Mark
Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma : The Swedish MCL complete Project
(
- Contribution to journal › Article
-
Mark
Exploring new prognostic biomarkers in Mantle Cell Lymphoma : a comparison of the circSCORE and the MCL35 score
(
- Contribution to journal › Article
-
Mark
Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation
(
- Contribution to journal › Article
-
Mark
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors
(
- Contribution to journal › Article
-
Mark
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe : The SCHOLAR-2 retrospective chart review study
(
- Contribution to journal › Article
-
Mark
Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: : a prospective cohort study
(
- Contribution to journal › Article
-
Mark
Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma : results from a retrospective worldwide registry
(
- Contribution to journal › Article